$ELOX
Eloxx Pharmaceuticals, Inc.

2018 Q2 Form 10-Q Financial Statement

#000156459018021183 Filed on August 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.560M $410.0K
YoY Change 2231.71% 41.38%
% of Gross Profit
Research & Development $4.150M $2.595M
YoY Change 59.92% 532.93%
% of Gross Profit
Depreciation & Amortization $25.00K $7.000K
YoY Change 257.14% -30.0%
% of Gross Profit
Operating Expenses $13.54M $3.179M
YoY Change 326.01% 127.07%
Operating Profit -$13.54M -$3.179M
YoY Change 326.01%
Interest Expense -$1.470M
YoY Change -5000.0%
% of Operating Profit
Other Income/Expense, Net $137.0K -$699.0K
YoY Change -119.6% 1065.0%
Pretax Income -$13.41M -$2.010M
YoY Change 567.16% 40.56%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$13.41M -$3.878M
YoY Change 245.69% 237.22%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$421.2K -$1.436M
COMMON SHARES
Basic Shares Outstanding 33.43M shares 26.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.41M $30.00K
YoY Change 211266.67% -96.3%
Cash & Equivalents $63.41M $13.36M
Short-Term Investments
Other Short-Term Assets $560.0K $250.0K
YoY Change 124.0% 47.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $63.97M $280.0K
YoY Change 22746.43% -71.5%
LONG-TERM ASSETS
Property, Plant & Equipment $302.0K $50.00K
YoY Change 504.0% -45.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K
YoY Change -80.0%
Total Long-Term Assets $302.0K $5.565M
YoY Change -94.57% -32.49%
TOTAL ASSETS
Total Short-Term Assets $63.97M $280.0K
Total Long-Term Assets $302.0K $5.565M
Total Assets $64.27M $5.845M
YoY Change 999.57% -36.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.098M $191.6K
YoY Change 995.01% 112.17%
Accrued Expenses $2.258M $330.3K
YoY Change 583.62% 28.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $410.0K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.356M $2.770M
YoY Change 57.26% 650.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.356M $2.770M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $4.360M $4.974M
YoY Change -12.34% 6.62%
SHAREHOLDERS EQUITY
Retained Earnings -$60.96M -$121.8M
YoY Change -49.96% 5.36%
Common Stock $121.0M $292.0K
YoY Change 41319.32% 42.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $59.92M $871.2K
YoY Change
Total Liabilities & Shareholders Equity $64.27M $5.845M
YoY Change 999.57% -36.64%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$13.41M -$3.878M
YoY Change 245.69% 237.22%
Depreciation, Depletion And Amortization $25.00K $7.000K
YoY Change 257.14% -30.0%
Cash From Operating Activities -$8.510M -$510.0K
YoY Change 1568.63% -29.17%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$40.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 53.67M 300.0K
YoY Change 17790.0%
NET CHANGE
Cash From Operating Activities -8.510M -510.0K
Cash From Investing Activities -40.00K 0.000
Cash From Financing Activities 53.67M 300.0K
Net Change In Cash 45.12M -210.0K
YoY Change -21585.71% -70.83%
FREE CASH FLOW
Cash From Operating Activities -$8.510M -$510.0K
Capital Expenditures -$40.00K $0.00
Free Cash Flow -$8.470M -$510.0K
YoY Change 1560.78% -29.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63412000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24049000
CY2018Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2017Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
102000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
458000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
355000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
63970000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
24506000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
302000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
278000
CY2018Q2 us-gaap Assets
Assets
64272000
CY2017Q4 us-gaap Assets
Assets
24784000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2098000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1530000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2258000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4356000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3423000
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
349000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
274000
CY2018Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
83000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
120607000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
60047000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60957000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38960000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
59916000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21361000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64272000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24784000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34869450
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27527738
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34869450
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27527738
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
97000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53668000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17169000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4150000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2595000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8544000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9560000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
584000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12953000
CY2018Q2 elox Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense
BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense
-167000
elox Business Combination Acquisition Related Costs And Adjustment To Estimate On Accrued Expense
BusinessCombinationAcquisitionRelatedCostsAndAdjustmentToEstimateOnAccruedExpense
594000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
13543000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
3179000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13543000
CY2018Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
8385
CY2017Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3179000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
137000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-699000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-13406000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3878000
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.77
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29695430
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4205277
us-gaap Share Based Compensation
ShareBasedCompensation
6913000
us-gaap Share Based Compensation
ShareBasedCompensation
21000
us-gaap Depreciation
Depreciation
46000
us-gaap Depreciation
Depreciation
13000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
625000
us-gaap Interest Expense Debt
InterestExpenseDebt
43000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
103000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-701000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
568000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1182000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
365000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
433000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14208000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5902000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
101000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
96000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-101000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2500000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3168000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
39361000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11171000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24151000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2250000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63512000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13421000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13360000
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
61000
elox Noncash Acquisition Of Treasury Shares
NoncashAcquisitionOfTreasuryShares
83000
elox Number Of Rare And Ultra Rare Disease Due To Premature Stoppage Of Codons
NumberOfRareAndUltraRareDiseaseDueToPrematureStoppageOfCodons
1800
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4394000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3393000
CY2018Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
761000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
8548000
CY2018Q2 us-gaap Prepaid Insurance
PrepaidInsurance
290000
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
242000
CY2017Q4 elox Contract Receivable Current
ContractReceivableCurrent
88000
CY2018Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
168000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
25000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
393000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
332000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
91000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54000
CY2018Q2 us-gaap Depreciation
Depreciation
25000
CY2017Q2 us-gaap Depreciation
Depreciation
7000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
700000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
402000
CY2018Q2 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
712000
CY2017Q4 elox Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
704000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
846000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
97000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53078000
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
495000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
31000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6913000
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
480049
elox Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
64374
elox Class Of Warrant Or Right Forfeited
ClassOfWarrantOrRightForfeited
68434
CY2018Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
347241
CY2018Q2 elox Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
347241
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.97
elox Class Of Warrant Or Right Exercised In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageExercisePrice
0.08
elox Class Of Warrant Or Right Forfeited In Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedInPeriodWeightedAverageExercisePrice
8.00
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.77
CY2018Q2 elox Class Of Warrant Or Right Exercisable In Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableInPeriodWeightedAverageExercisePrice
3.77
CY2017 elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P4Y2M26D
elox Class Of Warrant Or Right Expiration Period
ClassOfWarrantOrRightExpirationPeriod
P4Y4M24D
elox Class Of Warrant Or Right Exercisable Expiration Period
ClassOfWarrantOrRightExercisableExpirationPeriod
P4Y4M24D
CY2018Q2 elox Number Of Equity Based Compensation Plans
NumberOfEquityBasedCompensationPlans
2
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3215661
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1470141
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
667130
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
148435
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3870237
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1275487
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.91
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.44
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.13
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.69
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.66
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.72
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15174026
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28689787
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16685166
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.59
CY2018Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6178000
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6913000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
732212
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
elox Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit
10200000
CY2017Q2 elox Accumulated Undeclared Dividend
AccumulatedUndeclaredDividend
-483000
elox Accumulated Undeclared Dividend
AccumulatedUndeclaredDividend
-867000
CY2018Q2 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-13406000
CY2017Q2 elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-4361000
elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-21997000
elox Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-7423000
us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.08
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5088542
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20571719
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
elox Number Of Geographic Regions
NumberOfGeographicRegions
2

Files In Submission

Name View Source Status
0001564590-18-021183-index-headers.html Edgar Link pending
0001564590-18-021183-index.html Edgar Link pending
0001564590-18-021183.txt Edgar Link pending
0001564590-18-021183-xbrl.zip Edgar Link pending
elox-10q_20180630.htm Edgar Link pending
elox-20180630.xml Edgar Link completed
elox-20180630.xsd Edgar Link pending
elox-20180630_cal.xml Edgar Link unprocessable
elox-20180630_def.xml Edgar Link unprocessable
elox-20180630_lab.xml Edgar Link unprocessable
elox-20180630_pre.xml Edgar Link unprocessable
elox-ex106_216.htm Edgar Link pending
elox-ex311_9.htm Edgar Link pending
elox-ex312_8.htm Edgar Link pending
elox-ex321_7.htm Edgar Link pending
elox-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending